HEPATITIS C ELIMINATION AT THE LUMMI TRIBAL HEALTH CENTER

A Design Approach to a Public Health Challenge

JUSTIN IWASAKI MD MPH LUMMI TRIBAL HEALTH CENTER BELLINGHAM, WASHINGTON




INTRODUCE A DESIGN FRAMEWORK TO PUBLIC HEALTH PROGRAM DEVELOPMENT

OUTLINE THE COMPONENTS OF A HEPATITIS C ELIMINATION PROGRAM

REINFORCE THE NECESSITY OF HARM REDUCTION STRATEGIES AS A COMPONENT OF HEPATITIS C ELIMINATION

NO DISCLOSURES











WHY DID WE START TREATING HEPATITIS C?



80% OF NEW HEPATITIS C INFECTIONS OCCUR IN PEOPLE WHO INJECT DRUGS



20-30% OF PEOPLE WHO INJECT DRUGS BECOME INFECTED WITH HEPATITIS C WITHIN THE FIRST 2 YEARS OF STARTING TO INJECT DRUGS

AND 50% WITHIN 5 YEARS

WHY

NEALRLY 4 OUT OF 10
PATIENTS AT OUR OPIOID
TREATMENT PROGRAM
TESTED POSIVITE FOR
HEPATITIS C ANTIBODY



50% OF OUR PATIENTS WITH CHRONIC HEPATITIS C ARE UNDER AGE 40

HEPATITIS C IS A PUBLIC HEALTH PROBLEM



REDUCTION TO ZERO OF NEW CASES OF HEPATITIS C INFECTION ON THE LUMMI RESERVATION




SCREEN AND TREAT HIGH-RISK PATIENTS

TREATMENT AS PREVENTION

HARM REDUCTION AS PREVENTION

INITIAL APPROACH REQUIRED ROUTINE ENGAGEMENT WITH HEALTHCARE FOR 4-6 MONTHS



OUR EXISTING SYSTEM DIDN'T MEET THE NEEDS OF OUR PATIENTS

WE EXPECTED

SHEDULED OFFICE VISITS &
FOLLOW UP
SAFE STORAGE OF
MEDICATION
PREDICTABLE HOME
TELEPHONE FOLLOW-UP
FAMILY SUPPORT

PEOPLE NEEDED


FLEXIBILITY
WALK-INS
RIDES
HELP MANAGE MEDICATIONS
OUTREACH
BUILD SUPPORT



REDESIGN THE HEALTHCARE EXPERIENCE FOR PEOPLE WHO USE DRUGS

DESIGN THINKING PROCESS

Institute of Design at Stanford





HIRED HCV COORDINATOR AND ASSISTANT (1.5 FTE-> 2.0 FTE)

STREAMLINED WORKFLOWS

ON-SITE FIBROSCAN

MEDICATION MANAGEMENT

FOLLOW-UP AND OUTREACH

SINGLE VISIT READY TO TREAT PROGRAM

DAY 0 AB/RNA DAY 1

DATA MINING PREVIOUS HCV

RAPID HCV AB TEST

POSITIVE

HCV RNA WITH REFLEX TO GENOTYPE (STANDING ORDERS) BMP

LFT

INR CBC

FIBROSCAN

NEGATIVE

RE-SCREEN BASED ON EXPOSURE **HISTORY**

NO CHRONIC HCV


RETEST HCV RNA Q6 MONTH

CHRONIC HCV


1-2 WEEKS

START TREATMENT


HEPATITIS C SCREENING PROGRAM




GENERAL SCREENING




SCREENING AT OPIOID TREATMENT PROGRAM




LUMMI CASCADE OF CARE (2019)



HEPATITIS C ELIMINATION PROGRAM COMPONENTS



HEPATITIS C ELIMINATION PROGRAM COMPONENTS





HARM REDUCTION IS HCV PREVENTION

HARM REDUCTION PROGRAM CONTINUES TO EVOLVE IN RESPONSE TO PATIENT NEEDS



WEDNESDAY EVENINGS 5-6 PM

1 FOR 1

PROVIDED ~100 STERILE SYRINGES



INTEGRATED INTO THE PRIMARY CARE CLINIC

SAFE INJECTION SUPPLIES

36,000 STERILE SYRINGES



COMMUNITY BASED WITH SECONDARY EXCHANGE SITES

WEEKLY TRAINING FOR COMMUNITY MEMBERS

300,000+ STERILE SYRINGES



PRIMARY HEALTHCARE ACCESS POINT FOR MANY OF OUR PATIENTS WHO INJECT DRUGS

SAFER INJECTION SUPPLIES

HCV POINT OF CARE SCREENING

NALOXONE (NARCAN)

LOW-BARRIER ACCESS TO MEDICATIONS FOR OPIOID USE DISORDER (Buprenorphine) ~100 PATIENTS AND GROWING



FOLLOW UP AND OUTREACH

CHRONIC HCV FROM INJECTION DRUG USE

SCHIZOPHRENIA

OUR HOMELESS

SOMETIMES LIVED ON A SAIL BOAT

YWCA

POLYSUBSTANCE USE

NO PHONE

NO CAR

OUR
THIRD
PATIENT




THREE PATIENTS TREATED IN 2016

TODAY
TREATED OVER 100
NEARING THE GOAL OF
ELIMINATION



THANK YOU

PROGRAM COMPONENTS ARE CARRIED OUT BY A VARIETY OF TRAINED STAFF EXAMPLES FROM FIVE SITES



PROGRAM COMPONENTS ARE CARRIED OUT BY A VARIETY OF TRAINED STAFF

